Oh, since you guys obviously like biotech. Have a look a Clinuvel Pharmaceuticals. The reported the following Phase III results on December 21st and no run-up yet? Why not? Because it is an Australian company you think?
Preliminary Results An interim analysis of data from the first 4 months of treatment (March-October) in this 12 month trial was undertaken. The study employed a crossover comparison of afamelanotide (3 doses) and placebo (3 doses) in 100 patients. At dose intervals of 2 months, each patient received a single dose of either treatment.
Analysis of 2 treatment arms showed an overall reduction in the average number of phototoxic reactions. Thirty five patients with severe and/or moderate pain reported the greatest reduction in mean number of reactions (p=0.03, 95% CI). Analysis of pain severity was positively correlated with treatment, indicating that patient pain scores differed significantly between treatment groups (p=0.006, 95% CI).
Although the analysis of quality of life data is not yet complete, all 8 physicians involved in this trial reported a dramatic improvement in the patients’ ability to engage in outdoors activities. Safety reports from all academic centres are excellent to date.
This study will be completed by the end of December 2009, after which a full analysis of data will follow.